Алгоритмы диагностики и лечения язвенного колита

1. Шелыгин Ю.А., Ивашкин В.Т., Белоусова Е.А. и др. Язвенный колит (К51), взрослые. Колопроктология. 2023;22(1):10-44.

2. Travis S., Dinesen L. Remission intrials of ulcerative colitis: what does it mean? Pract Gastroenterology. 2010;30:17–20.

3. Григорьева Г.А., Мешалкина Н.Ю. О проблеме системных проявлений воспалительных заболеваний кишечника. Фарматека. 2011;15:44-49.

4. Долгалёв И.В. Язвенный колит: клиника, диагностика, лечение: учебное пособие Томск: Изд-во СибГМУ, 2021.

5. Бикбавова Г.Р., Ливзан М.А., Турчанинов Д.В., Заставная А.А. Язвенный колит – от предрасполагающих факторов до диагноза. Доказательная гастроэнтерология. 2019;8(4-5):5-10.

6. Travis S.P., Jewell D.P. Ulcerative colitis: clinical presentation and diagnosis. In: Satsangi J., Sutherland L.R, editors. Inflammatory Bowel Diseases. London: Churchill Livingstone. 2003:169–81.

7. Lucendo A.J., Arias Á., Roncero Ó., Hervías D., et al. Anemia at the time of diagnosis of inflammatory bowel disease: Prevalence and associated factors in adolescent and adult patients. Sao Paulo Med J. 2014;132(3):140-6.

8. Irwin J.R., Ferguson E., Simms L.A., et al. Detectable Laboratory Abnormality Is Present up to 12 Months Prior to Diagnosis in Patients with Crohn»s Disease. Dig Dis Sci. 2019 Feb;64(2):503-517.

9. Cherfane C.E., Gessel L., Cirillo D., et al. Monocytosis and a Low Lymphocyte to Monocyte Ratio Are Effective Biomarkers of Ulcerative Colitis Disease Activity. Inflamm Bowel Dis. 2015 Aug;21(8):1769-75.

10. Feng J.R., Qiu X., Wang F., et al. Diagnostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Crohn's Disease. Gastroenterol Res Pract. 2017. https://doi.org/10.1155/2017/3526460

11. Yoon J.Y., Park S.J., Hong S.P., et al. Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis. Dig Dis Sci. 2014 Apr;59(4):829-37.

12. Yamamoto-Furusho J.K., Sánchez-Osorio M., Uribe M. Prevalence and factors associated with the presence of abnormal function liver tests in patients with ulcerative colitis. Ann Hepatol. 2010 Oct-Dec;9(4):397-401.

13. Archampong E.Q., Harris J., Clark C.G. The absorption and secretion of water and electrolytes across the healthy and the diseased human colonic mucosa measured in vitro. Gut. 1972 Nov;13(11):880-6.

14. Maharshak N., Arbel Y., Gal-Oz A., et al. Comparative analysis of Bayer wide-range C-reactive protein (wr-CRP) and the Dade-Behring high sensitivity C-reactive protein (hs-CRP) in patients with inflammatory bowel disease. J Dig Dis. 2008 Aug;9(3):140-3.

15. Weber P., Husemann S., Vielhaber H., et al. Coagulation and fibrinolysis in children, adolescents, and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1999 Apr;28(4):418-422.

16. Issa M., Vikayapal A., Gracham M.B., et al. Impact of Clostridium difficile in inflammatory bowel disease patients. Clin Gastroenterol Hepatol. 2007;5:345-351.

17. Rodeman J.F., Dubberke E.R., Reske K.A., et al. Incidence of Clostridium difficile in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:339-344.

18. Issa M., Ananthakrishnan A.N., Binion D.G. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:1432-42.

19. Nguyen G.C., Kaplan G.G., Harris M.L., et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103:1443-50.

20. Kim J.J., Simpson N., Klipfel N., et al. Cytomegalovirus infection in patients with active inflammatory bowel disease. Dig Dis Sci. 2010 Apr;55(4):1059-65. https://dx.doi.org/10.1007/s10620-010-1126-4

21. Levin A., Yaari S., Stoff R., et al. Diagnosis of Cytomegalovirus Infection during Exacerbation of Ulcerative Colitis. Digestion. 2017;96(3):142-148. https://dx.doi.org/10.1159/000479865

22. Mogan G.R., et al. Toxic megacolon in ulcerative colitis complicated by pneumomediastinum: report of two cases. Gastroenterology. 1980;79(3):559-562.

23. Lin W.C., Chang C.W., Chen M.J., et al. Effectiveness of sigmoidoscopy for assessing ulcerative colitis disease activity and therapeutic response. Medicine (Baltimore). 2019 May;98(21):e15748. https://dx.doi.org/10.1097/MD.0000000000015748

24. Schroeder K.Н., Tremaine W., Ilstrup D.М. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-9.

25. Annese V., Daperno M., Rutter M.D., et al. European evidence based consensus for endoscopy in inflammatory bowel disease. Journal of Crohn’s and Colitis. 2013;7(12):982-1018.

26. Tanaka M., Saito H., Fukuda S., et al. Simple mucosal biopsy criteria differentiating among Crohn disease, ulcerative colitis, and other forms of colitis: measurement of validity. Scand J Gastroenterol. 2000 Mar;35(3):281-6.

27. Куваев Р., Кашин С., Завьялов Д. Роль колоноскопии в диагностике дисплазии и рака толстой кишки при язвенном колите. Врач. 2016;2:70-76.

28. Parente F., Greco S., Molteni M., et al. Role of early ultrasound in detecting inflammatory intestinal disorders and identifying their anatomical location within the bowel. Alimentary Pharmacology and Therapeutics. 2003;18:1009-1016.

29. Baltarowich O.H., Scoutt L.M., Hamper U.M. Nongynecologic findings on pelvic ultrasound: focus on gastrointestinal diseases. Ultrasound Quarterly. 2012;28(2):65-85.

30. Smith R., Taylor K., Friedman A.B., et al. Systematic Review: Clinical Utility of Gastrointestinal Ultrasound in the Diagnosis, Assessment and Management of Patients With Ulcerative Colitis. J Crohns Colitis. 2020 May 21;14(4):465-479. https://dx.doi.org/10.1093/ecco-jcc/jjz163

31. Gashin L., Villafuerte-Galvez J., Leffler D.A., et al. Utility of CT in the emergency department in patients with ulcerative colitis. Inflamm Bowel Dis. 2015 Apr;21(4):793-800. https://dx.doi.org/10.1097/MIB.0000000000000321

32. Милько В.И., Минцер О.П., Топчий Т.В., Корсуновский А.А. Клиническая оценка данных ирригоскопии при неспецифическом язвенном колите. Вестник рентгенологии и радиологии. 1983;5:46-50.

33. Silverberg M., Satsangi J., Ahmad T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5–36.

34. Truelove S., Witts L., et al. Cortisone in ulcerative colitis; final report on a therapeutic trial Br Med J. 1955;2:1041-1048.

35. Dignass A., Eliakim R., Magro F., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis J Crohns Colitis. 2012 Dec;6(10):965-90. https://dx.doi.org/10.1016/j.crohns.2012.09.003

36. Sandborn W.J., Sands B.E., Vermeire S., et al. Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program. Therap Adv Gastroenterol. 2022 Dec 5;15:17562848221136331. https://dx.doi.org/10.1177/17562848221136331

37. Chen J., Andrews J., Kariyawasam V., et al. IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: acute severe ulcerative colitis – evidence-based consensus statements. Aliment Pharmacol Ther. 2016 Jul;44(2):127-44.